Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

June 9, 2011

Men May Be at Greater Risk Than Women for Developing HPV-Related Cancers

Author(s):

Jon Garinn

HPV-positive oral cancers are on the rise.

A new analysis from the National Cancer Institute suggests that the number of HPV-positive oral cancers among men could rise significantly in the next decade, possibly surpassing HPV-positive cervical cancers among women.

The genital human papillomavirus (HPV) is the most common sexually transmitted infection in the U.S., according to the Centers for Disease Control and Prevention. About 20 million Americans are currently infected and about 6 million are infected each year.

Using population-based cancer registry data, the researchers found that between 1988 and 2004, oropharyngeal cancers related to HPV increased by 225 percent, with men accounting for the majority of cases. Relying on U.S. Census projections and age-period-cohort models, they projected a 27 percent rise in cases by 2020.

More than 40 types of HPV are spread during genital, oral or anal sex with an infected partner—some are low-risk (wart-causing) while others are high-risk (cancer-causing). In most cases, the body's own immune system gets rid of HPV within about two years of infection. But if the body cannot clear the infection, it can develop into several cancers, including oropharyngeal and cervical, which is the second leading cause of cancer deaths in women worldwide.

Gardasil, the only approved vaccine for young men and women, is effective against two types of cancer-causing HPV and two types of wart-causing HPV. Cervarix is an HPV vaccine approved only for women.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of a head and neck
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Related Content
Advertisement
In HPV15+ first-line recurrent and/or metastatic head and neck cancer, PDS0101 and Keytruda elicited notable overall survival: © stock.adobe.com.
September 13th 2025

PDS0101 Plus Keytruda Elicits Survival Response in Head and Neck Cancer

Alex Biese
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
September 13th 2025

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
Keytruda was approved for locally advanced head and neck cancer before and after surgery: © stock.adobe.com.
September 13th 2025

FDA Approves Perioperative Keytruda for Locally Advanced Head and Neck Cancer

Spencer Feldman
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
September 13th 2025

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Image of neck.
September 13th 2025

GLP-1 Drugs Linked to Fewer Obesity-Related Cancers

Ariana Pelosci
Image of woman holding her neck.
September 13th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
Related Content
Advertisement
In HPV15+ first-line recurrent and/or metastatic head and neck cancer, PDS0101 and Keytruda elicited notable overall survival: © stock.adobe.com.
September 13th 2025

PDS0101 Plus Keytruda Elicits Survival Response in Head and Neck Cancer

Alex Biese
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
September 13th 2025

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
Keytruda was approved for locally advanced head and neck cancer before and after surgery: © stock.adobe.com.
September 13th 2025

FDA Approves Perioperative Keytruda for Locally Advanced Head and Neck Cancer

Spencer Feldman
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
September 13th 2025

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Image of neck.
September 13th 2025

GLP-1 Drugs Linked to Fewer Obesity-Related Cancers

Ariana Pelosci
Image of woman holding her neck.
September 13th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.